The lipid management pathway for secondary prevention of cardiovascular disease has been updated. Changes include:
- A statement has been added to ensure statin intolerance pathway has a clear emphasis
- Further highlighting of the position of icosapent ethyl (Vaskepa®)
- Inclisiran option for prescribing has been made clearer
The updated pathway is available on the clinical guidance and pathways page, along with links to other lipid management resources.